Dr. Chung is the Project Manager at the Sanford-Burnham Medical Research Institute's screening center.
Dr. Chung received his Ph.D. in Bioinorganic Chemistry from UC Berkeley with postdoctoral work at SmithKline French and Merck Laboratories.
Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity.
Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME
Mol Pharmacol. 2010 Oct;78(4):560-8
Assay format as a critical success factor for identification of novel inhibitor chemotypes of tissue-nonspecific alkaline phosphatase from high-throughput screening.
Chung TD, Sergienko E, Millán JL
Molecules. 2010 May;15(5):3010-37
Design and synthesis of selective inhibitors of placental alkaline phosphatase.
Lanier M, Sergienko E, Simão AM, Su Y, Chung T, Millán JL, Cashman JR
Bioorg Med Chem. 2010 Jan 15;18(2):573-9
Use of moving optical gradient fields for analysis of apoptotic cellular responses in a chronic myeloid leukemia cell model.
Forster AH, Wang MM, Butler WF, Chachisvilis M, Chung TD, Esener SC, Hall JM, Kibar O, Lykstad K, Marchand PJ, Mercer EM, Pestana LM, Sur S, Tu E, Yang R, Zhang H, Kariv I
Anal Biochem. 2004 Apr 1;327(1):14-22
Improvement of "hit-to-lead" optimization by integration of in vitro HTS experimental models for early determination of pharmacokinetic properties.
Kariv I, Rourick RA, Kassel DB, Chung TD
Comb Chem High Throughput Screen. 2002 Sep;5(6):459-72
Real-time monitoring in vitro transcription using molecular beacons.
Liu J, Feldman P, Chung TD
Anal Biochem. 2002 Jan 1;300(1):40-5
View All Publications
Modulation of quinone PCET reaction by Ca(2+) ion captured by calixquinone in water.
Kim YR, Kim RS, Kang SK, Choi MG, Kim HY, Cho D, Lee JY, Chang SK, Chung TD
J Am Chem Soc. 2013 Nov 25;
Identification of the GPR55 Antagonist Binding Site Using a Novel Set of High Potency GPR55 Selective Ligands.
Kotsikorou E, Sharir H, Shore DM, Hurst DP, Lynch DL, Madrigal KE, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak LS, Croatt MP, Abood ME, Reggio PH
Biochemistry. 2013 Nov 25;
Thomas "TC" Chung's Research Focus
Dr. Chung is the Project Manager at the Sanford-Burnham Medical Research Institute's screening center. Since September 2007, Dr. Chung has been responsible for strategic and tactical operations for HTS and chemical genomics, with over 20 years in drug discovery in roles of increasing responsibility from bench R&D to Executive for major several pharmaceutical companies and (DuPont Pharmaceutical, BMS, Merck, and GSK) and start-ups (Pharmacopeia and Genoptix), to Chief Scientific Officer. He has built and led world-class R&D teams and facilities that developed, acquired and integrated novel technologies in imaging, signal generation and detection, liquid handling, miniaturization, IT, high-throughput screening, biochemical and cell-based assay development, laboratory automation and robotics, compound management, Lead optimization, ADME/Tox profiling and analytical chemistry (HPLC/MS). Dr. Chung has managed discovery programs in cardiovascular, CNS, infectious, inflammatory and cancer diseases, with expertise in biochemistry, molecular and cellular biology, over 35 papers and book chapters, 10 issued and pending patents.
About Thomas "TC" Chung
Dr. Chung is a recognized thought leader in the HTS field and is an emeritus President of the Society for Biomolecular Screening, member of the Editorial Board of the J. Biomol. Screening, and the past and present Awards Committee of the new Society for Laboratory Automation and Screening (SLAS). He and his former group at DuPont Pharmaceuticals were the originators of the 'Z-factor' which is the most cited paper in the HTS field.